Results 131 to 140 of about 1,619,601 (310)

Figure S1 from <i>In Vivo</i> Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models

open access: gold, 2023
Jasmien Cornillie   +11 more
openalex   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14) [PDF]

open access: yes, 2018
Levonis, Stephan M   +3 more
core   +1 more source

Inhibitor-induced enzyme activation in organic solvents.

open access: hybrid, 1988
Alan J. Russell, Alexander M. Klibanov
openalex   +1 more source

The B12-independent glycerol dehydratase activating enzyme from Clostridium butyricum cleaves SAM to produce 5′-deoxyadenosine and not 5′-deoxy-5′-(methylthio)adenosine

open access: green, 2021
William G. Walls   +6 more
openalex   +2 more sources

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

open access: yesMolecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy